Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
Open accessAbstract
BACKGROUND: Rituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both antibodies are delivered by the intravenous (IV) route, but recently subcutaneous (SC) formulations have been developed. Subcutaneous administration of mAbs can offer substantial patient and resource benefits compared with IV, but SC administration of some mAbs can be limited by drug volume. Recombinant human hyaluronidase (rHuPH20) temporarily degrades hyaluronan, allowing SC delivery of drug volumes that might not otherwise be feasible. METHODS: Clinical trials assessing coformulation of rituximab or trastuzumab with rHuPH20 for SC administration were reviewed. RESULTS: Phase I trials of rituximab SC maintenance therapy in patients with follicular lymphoma and trastuzumab SC in healthy volunteers and patients with early breast cancer have demonstrated substantially shorter administration times and comparable tolerability and pharmacokinetics compared with IV formulations. Rituximab SC 1400-mg and trastuzumab SC 600-mg doses were identified for further study. Phase III clinical data for rituximab SC 1400 mg have shown comparable efficacy to rituximab IV, and initial clinical data suggest comparable efficacy of trastuzumab SC 600 mg and the IV formulation. CONCLUSION: Coformulation with rHuPH20 may enable effective, well-tolerated, cost-effective, and convenient SC administration of rituximab and trastuzumab. Additional studies are ongoing.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Subcutaneous co-formulations with rHuPH20 were approved for the mAbs trastuzumab and rituximab for use in the treatment of HER2-positive breast cancer and lymphoma, respectively.
“Subcutaneous co-formulations with rHuPH20 were approved for the mAbs trastuzumab and rituximab for use in the treatment of HER2-positive breast cancer and lymphoma, respectively [12].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,607 · see citing works
Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products
Verzijl, N., DeGroot, J., Thorpe, S. R., Bank, R. A., Shaw, J., Lyons, T. J., Bijlsma, J. W. J., Lafeber, F. P. J. G., Baynes, J., & TeKoppele, J. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006700200 · Cited by 964 · see citing works
General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
Mager, D. E., & Jusko, W. J. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1014414520282 · Cited by 605 · see citing works
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497 · see citing works
Miller, R. W., Young, J. L., & Novakovic, B. (1995) · Cancer · doi:10.1002/1097-0142(19950101)75:1+ · Cited by 357 · see citing works
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351 · see citing works
Self-citationA recombinant human enzyme for enhanced interstitial transport of therapeutics
Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282 · see citing works
Stilgenbauer, S., Zenz, T., Winkler, D. F. H., Bühler, A., Schlenk, R. F., Groner, S., Busch, R. M., Hensel, M., Dührsen, U., Finke, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1128 · Cited by 269 · see citing works
Management of venous port systems in oncology: a review of current evidence
Vescia, S., Baumgärtner, A. K., Jacobs, V. R., Kiechle-Bahat, M., Rody, A., Loibl, S., & Harbeck, N. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm272 · Cited by 264 · see citing works
Vogel, W. H. (2010) · Clinical journal of oncology nursing · doi:10.1188/10.cjon.e10-e21 · Cited by 204 · see citing works
Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
Wang, D. D., Zhang, S., Zhao, H., Men, A. Y., & Parivar, K. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337512 · Cited by 192 · see citing works
Wynne, C., Harvey, V. J., Schwabe, C., Waaka, D., McIntyre, C., & Bittner, B. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012436560 · Cited by 125 · see citing works
Evolution of Diabetes Insulin Delivery Devices
Sélam, J.-L. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400302 · Cited by 116 · see citing works
Kagan, L., Turner, M. R., Balu‐Iyer, S. V., & Mager, D. E. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0578-3 · Cited by 105 · see citing works
Sehn, L. H., Donaldson, J., Filewich, A., Fitzgerald, C., Gill, K. K., Runzer, N., Searle, B., Souliere, S., Spinelli, J. J., Sutherland, J., et al. (2007) · Blood · doi:10.1182/blood-2006-11-059469 · Cited by 100 · see citing works
Harb, G., Lebel, F. M., Battikha, J. P., & Thackara, J. W. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903432900 · Cited by 74 · see citing works
Thomas, J. R., Yocum, R. C., Haller, M. F., & von Gunten, C. F. (2007) · Journal of Palliative Medicine · doi:10.1089/jpm.2007.0126 · Cited by 56 · see citing works
Vaughn, D. E., Yocum, R. C., Muchmore, D. B., Sugarman, B. J., Vick, A., Bilinsky, I. P., & Frost, G. I. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0013 · Cited by 54 · see citing works
Salar, A., Casao, D., Cervera, M., et al. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00713.x · Cited by 45 · see citing works
Thomas, J. R., Wallace, M. S., Yocum, R. C., Vaughn, D. E., Haller, M. F., & Flament, J. (2009) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.03.009 · Cited by 41 · see citing works
Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review
Chan, A. L. F., Leung, H. W. C., Lu, C., et al. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l504 · Cited by 31 · see citing works
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation
Yokoyama, H., Lundqvist, A., Su, S., & Childs, R. W. (2010) · Blood · doi:10.1182/blood-2010-06-291104 · Cited by 29 · see citing works
Perez-Ellis, C., Gonçalvès, A., Jacquemier, J. D., et al. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181931277 · Cited by 28 · see citing works
Yin, A., Li, J., Hurst, D. W., & Visich, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13108 · Cited by 16 · see citing works
Salar, A., Bouabdallah, R., McIntyre, C., Sayyed, P. Z., & Bittner, B. (2010) · Blood · doi:10.1182/blood.v116.21.2858.2858 · Cited by 12 · see citing works
Davies, A. J., Merli, F., Mihaljevik, B., Siritanaratkul, N., Solal‐Céligny, P., Boehnke, A., Berge, C., McIntyre, C., Barrett, M., & Macdonald, D. A. (2012) · Blood · doi:10.1182/blood.v120.21.1629.1629 · Cited by 8 · see citing works
Salar, A., Avivi, I. M., Larouche, J.-F., Janíková, A., Pereira, J. C., Brewster, M., Catalani, O., McIntyre, C., Sayyed, P. Z., & Haynes, A. (2012) · Blood · doi:10.1182/blood.v120.21.1641.1641 · Cited by 8 · see citing works
Assouline, S. E., Buccheri, V., Delmer, A. J., Doelken, G., Gaïdano, G., McIntyre, C., Brewster, M., Hourcade‐Potelleret, F., Sayyed, P. Z., & Badoux, X. C. A. (2012) · Blood · doi:10.1182/blood.v120.21.1637.1637 · Cited by 6 · see citing works
Nagro, C. J. D., Mao, C.-P., Brovarney, M., et al. (2010) · Blood · doi:10.1182/blood.v116.21.3980.3980 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447 · see citing works
High-concentration protein formulations: How high is high?
Garidel, P., Kuhn, A. B., Schäfer, L. V., Karow-Zwick, A. R., & Blech, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.06.029 · Cited by 187 · see citing works
Fixed Dosing of Monoclonal Antibodies in Oncology
Hendrikx, J. J. M. A., Haanen, J. B. A. G., Voest, E. E., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0167 · Cited by 168 · see citing works
Rummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw685 · Cited by 154 · see citing works
Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125 · see citing works
Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70005-1 · Cited by 114 · see citing works
Wasserman, R. L. (2017) · Immunotherapy · doi:10.2217/imt-2017-0092 · Cited by 77 · see citing works
Rituximab by subcutaneous route
Solal-Celigny, P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1024651 · Cited by 13 · see citing works
- Authors
- Shpilberg, O., & Jackisch, C.
- Affiliations
- Sana Klinikum Offenbach (DE)
- Corresponding author
- Jackisch, C
- Venue
- British Journal of Cancer
- Published
- 2013-09
- Volume
- 109
- Issue
- 6
- Pages
- 1556-1561
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC3776971
- OpenAlex
- W1976956940
- Cited by
- 138
- References
- 29
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 12 · 2023: 6 · 2022: 15 · 2021: 13 · 2020: 10 · 2019: 10 · 2018: 18 · 2017: 15 · 2016: 7 · 2015: 10 · 2014: 11
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- rituximab, trastuzumab, subcutaneous administration, recombinant human hyaluronidase, rHuPH20, monoclonal antibodies, follicular lymphoma, early breast cancer, pharmacokinetics, tolerability, administration time, cost-effectiveness
- MeSH terms
- Trastuzumab, Rituximab, Antineoplastic Agents, Female, Humans, Hyaluronoglucosaminidase, Injections, Subcutaneous, Lymphoma, Follicular, Male, Recombinant Proteins, Antibodies, Monoclonal, Murine-Derived, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
